Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

Company Overview

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness.

The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.

Founded in 2016, Fulcrum conducts drug discovery and development primarily in the United States. Its programs and development priorities may change as clinical research progresses.

Key Stats

• Today's Range: $3.73 to $3.80
• 50-Day Range: $3.64 to $3.85
• 52-Week Range: $2.83 to $15.74
• Volume: 881,065 shs
• Average Volume: 1.59 million shs
• Market Capitalization: $288.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.20
• Consensus Rating: Reduce

Fulcrum Therapeutics Stock Analysis - MarketRank™

Fulcrum Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 672nd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Fulcrum Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 7 hold ratings, and 4 sell ratings.

Upside Potential

Fulcrum Therapeutics has a consensus price target of $8.20, representing about 116.1% upside from its current price of $3.80.

Amount of Analyst Coverage

Fulcrum Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Fulcrum Therapeutics are expected to grow in the coming year, from ($0.60) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fulcrum Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fulcrum Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fulcrum Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.10% of the float of Fulcrum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Fulcrum Therapeutics has a short interest ratio ("days to cover") of 4.82.

Change versus previous month

Short interest in Fulcrum Therapeutics has recently decreased by 4.66%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fulcrum Therapeutics does not currently pay a dividend.

Dividend Growth

Fulcrum Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: -0.61

News Sentiment

Fulcrum Therapeutics has a news sentiment score of -0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Fulcrum Therapeutics this week, compared to 4 articles on an average week.

MarketBeat Follows

1 people have added Fulcrum Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fulcrum Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.30% of the stock of Fulcrum Therapeutics is held by insiders.

Percentage Held by Institutions

89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/12/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FULC
• CIK: 1680581
• Web: www.fulcrumtx.com
• Phone: (617) 651-8851
• Fax: N/A
• Employees: 55
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Fulcrum Therapeutics: $8.20
• High Price Target: $24.00
• Low Price Target: $3.00
• Potential Upside/Downside: +117.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -25.38%
• Return on Assets: -24.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 31.35
• Quick Ratio: 31.35

Sales & Book Value

• Annual Sales: $80 million
• Price / Sales: 3.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.45 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 76,380,000
• Free Float: 70,806,000
• Market Cap: $288.33 million
• Optionable: Optionable
• Beta: 2.82